CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Meda Pharmaceuticals Inc. v. Perrigo UK FINCO Limited Partnership

1:16-cv-00794

Overview

Case Number 1:16-cv-00794
Filing Date 2016-09-09
Status Terminated
Termination Date 2017-07-07
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Perrigo Pharmaceuticals Co. Operating Company

Represented By

2 Attorneys Listed

David A. Bilson

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200
Fax: +1 (302) 655-4210

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

Perrigo Company NPE (Individual / Inventor)

Represented By

2 Attorneys Listed

David A. Bilson

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200
Fax: +1 (302) 655-4210

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

Perrigo UK FINCO Limited Partnership NPE (University / Research)

Represented By

3 Attorneys Listed

Steven H. Sklar

Email: ssklar@leydig.com

David A. Bilson

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200
Fax: +1 (302) 655-4210

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

Plaintiff

Cipla Ltd. Operating Company

Represented By

4 Attorneys Listed

John G. Day

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Andrew Colin Mayo

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Steven J. Balick

Ashby & Geddes

Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Stamatios Stamoulis

Stamoulis & Weinblatt LLC

Tel: +1 (302) 999-1540

Stamoulis & Weinblatt LLC, 800 N. West Street, Third Floor

Meda Pharmaceuticals Inc. Operating Company

Represented By

11 Attorneys Listed

Uma N. Everett

Email: ueverett@sternekessler.com

Rami Bardenstein

UNDELIVERABLE 12/28/2016

UNDELIVERABLE 12/28/2016

Mark F. Evens

Email: mevens@skgf.com

Joshua I. Miller

Email: jmiller@skgf.com

Josephine J. Kim

Email: joskim@sternekessler.com

John G. Day

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Andrew M. Nason

Email: anason@skgf.com

Andrew Colin Mayo

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Adam C. LaRock

Email: alarock@sternekessler.com

Steven J. Balick

Ashby & Geddes

Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Stamatios Stamoulis

Stamoulis & Weinblatt LLC

Tel: +1 (302) 999-1540

Stamoulis & Weinblatt LLC, 800 N. West Street, Third Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 13 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials 5 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (13): GB 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (5 found):
PTAB: 5
USPTO PTAB Trial 2020-01-31
IPR2020-00371

GlaxoSmithKline Consumer Healthcare Holdings (US) LLC v. Cipla Limited et al.

U.S. Continuation Sibling (9901585)
Status: Institution Denied
USPTO PTAB Trial 2020-01-31
IPR2020-00370

GlaxoSmithKline Consumer Healthcare Holdings (US) LLC v. Cipla Limited et al.

U.S. Continuation Sibling (9259428)
Status: Institution Denied
USPTO PTAB Trial 2020-01-31
IPR2020-00369

GlaxoSmithKline Consumer Healthcare Holdings (US) LLC v. Cipla Limited et al.

U.S. Continuation Sibling (8168620)
Status: Institution Denied
USPTO PTAB Trial 2020-01-31
IPR2020-00368

GlaxoSmithKline Consumer Healthcare Holdings (US) LLC v. Cipla Limited et al.

Asserted Patent
Status: Institution Denied
USPTO PTAB Trial 2017-02-02
IPR2017-00807

Argentum Pharmaceuticals LLC v. Cipla Limited

U.S. Continuation Sibling (8168620)
Status: Terminated-Settled
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

3 Patents

There are 3 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8168620
Combination of azelastine and steroids
Filed: 2003-06-13
Issued: 2012-05-01
Expired (Term Ended) +987d PTA
Expires: 2026-02-24
US9259428
Combination of azelastine and fluticasone for nasal administration
Filed: 2015-03-18
Issued: 2016-02-16
Active (8.3 yrs remaining)
Expires: 2035-03-18
US8163723
Combination of azelastine and steroids
Filed: 2010-09-10
Issued: 2012-04-24
Expired (Term Ended)
Expires: 2023-08-29

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+987 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

17

Dispositive

0

Granted

0

Denied

0

Pending / Review

9

Motions by Category

Procedural / Extension Motion 16 Claim Construction / Markman Filing 1

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending
SO ORDERED, re 32 Joint STIPULATION TO EXTEND TIME Certain Case Management Deadlines to July 19, 2017 filed by Meda Pharmaceuticals Inc. Signed by Judge Leonard...
Entry #— • 2017-06-16
Procedural / Extension Motion Pending / Under Review
Joint STIPULATION TO EXTEND TIME Certain Case Management Deadlines to July 19, 2017 - filed by Meda Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 06/14...
Entry #32 • 2017-06-14 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 31 STIPULATION TO EXTEND TIME Exchange of Infringement and Invalidity Contentions to filed by Meda Pharmaceuticals Inc. Signed by Judge Leonard P...
Entry #— • 2017-05-16
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME Exchange of Infringement and Invalidity Contentions to - filed by Meda Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 05/10/2...
Entry #31 • 2017-05-10 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 28 STIPULATION TO EXTEND TIME for Initial Disclosures to March 27, 2017 filed by Perrigo Company, Perrigo UK FINCO Limited Partnership, Perrigo P...
Entry #— • 2017-03-22
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for Initial Disclosures to March 27, 2017 - filed by Perrigo Company, Perrigo Pharmaceuticals Co., Perrigo UK FINCO Limited Partnersh...
Entry #28 • 2017-03-20 Document →

Docket Entries

(77 total)
Pleading / Complaint

COMPLAINT filed against Perrigo Company, Perrigo Pharmaceuticals Co., Perrigo UK FINCO Limited Partnership - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 26208.) - filed by Meda Pharmaceuticals Inc., Cipla Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(sar) (Entered: 09/09/2016)

Entry #1 • 2016-09-09
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sar) (Entered: 09/09/2016)

Entry #2 • 2016-09-09
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: August 1, 2016. Date of Expiration of Patent: February 24, 2026 and June 13, 2023.Thirty Month Stay Deadline: 2/1/2019. (sar) (Entered: 09/09/2016)

Entry #3 • 2016-09-09
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,168,620; 9,259,428;. (sar) (Entered: 09/09/2016)

Entry #4 • 2016-09-09
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Mylan N.V. for Meda Pharmaceuticals Inc. filed by Meda Pharmaceuticals Inc.. (sar) (Entered: 09/09/2016)

Entry #5 • 2016-09-09
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc